Trametinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Trametinib: From BRAF-Mutant Melanoma to Choroideremia
One-Sentence Summary
Trametinib is a MEK inhibitor whose established oncology use (reflected throughout this evidence pack's trial and literature data) is in BRAF V600-mutant melanoma, typically combined with a BRAF inhibitor such as dabrafenib. The TxGNN model's top-ranked prediction for this drug is Choroideremia, but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure model association with no mechanistic or empirical backing found in this pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack's regulatory fields (original_indications empty, original_moa flagged as a data gap); trial/literature evidence throughout the pack consistently associates trametinib with BRAF V600-mutant melanoma, usually as part of a dabrafenib + trametinib regimen |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is marked as a data gap in this evidence pack. Based on the mechanistic notes attached to other predicted indications in this batch, trametinib is an allosteric MEK1/2 inhibitor acting on the MAPK/ERK signalling pathway, which underlies its established efficacy in BRAF V600-mutant melanoma.
Choroideremia, however, is an inherited retinal degeneration caused by loss-of-function mutations in the CHM gene (REP1 protein deficiency) — a pathway with no known connection to MAPK/ERK signalling. The evidence pack's own repurposing rationale for this indication states there is no known pathological link between the two, and explicitly flags this candidate as a likely false positive arising purely from graph-embedding similarity in the TxGNN model.
In short: the mechanistic story that supports trametinib in melanoma does not extend to choroideremia. This prediction should be treated as a model artifact rather than a biologically grounded hypothesis unless independent mechanistic or experimental data emerges.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
No authorizations on record — Trametinib is not marketed in New Zealand (0 licenses in the tracked database).
Cytotoxicity
Trametinib is an antineoplastic agent (MEK inhibitor used in oncology), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK inhibitor; non-cytotoxic mechanism) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA package insert warnings/contraindications are recorded as a Blocking data gap — DG001 — which prevents a complete initial safety assessment for this drug.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (choroideremia) has no clinical trial or literature support and lacks a plausible mechanistic link to trametinib's known MAPK/ERK-based pharmacology — the evidence pack itself flags it as a probable false positive.
To proceed, the following is needed:
- TFDA/package insert safety data (warnings, contraindications) to close data gap DG001, which is currently blocking any safety evaluation for this drug
- Independent mechanistic or preclinical evidence linking MEK inhibition to CHM/REP1-related retinal degeneration before this specific indication is reconsidered
- Confirmed DrugBank MOA and original-indication data to close data gap DG002
- Consider redirecting evaluation effort toward the more evidence-backed candidates in this same prediction batch — e.g., BRAF V600-mutant non-cutaneous/acral melanoma subtypes (L2–L3 evidence, "Research Question" stage), which have real supporting trials and a coherent mechanistic rationale, unlike choroideremia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.